Sort
10,766 grants matching “checkpoint inhibitor”
Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
$642,579Stefanie Sarantopoulos · Duke University · R01 · FY2017 · HL
Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
$642,579Stefanie Sarantopoulos · Duke University · R01 · FY2018 · HL
Immune receptor degradation for immune evasion of head and neck cancer
$642,488Dohun Pyeon · Henry Ford Health + Michigan State University Health Sciences · R01 · FY2025 · DE
Deoxyuridine Contamination and Innate Immune Signaling
$642,394Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Re-engineering differential regulation of ferroptosis in melanoma microenvironment
$642,352Yuri Bunimovich · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Re-engineering differential regulation of ferroptosis in melanoma microenvironment
$642,352Yuri Bunimovich · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Project 3: Tools for Capturing Immune Cell/Cancer Cell Interactions in Cancer Immunotherapies and Combination Immunotherapies
$642,335James R. Heath · California Institute Of Technology · U54 · FY2016 · CA
Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$642,266David E Fisher · Massachusetts General Hospital · P01 · FY2025 · CA
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
$642,150Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2017 · CA
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$641,997Katerina Abigail Politi · Yale University · R01 · FY2023 · CA
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
$641,504Jeffrey M Peters · Pennsylvania State University, The · R01 · FY2022 · CA
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
$641,503Jeffrey M Peters · Pennsylvania State University, The · R01 · FY2023 · CA
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
$641,386Garret A Fitzgerald · University Of Pennsylvania · R01 · FY2019 · HL
Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer
$641,336Zihai Li · Ohio State University · R01 · FY2024 · CA
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer
$641,281Dohun Pyeon · Michigan State University · R01 · FY2022 · DE
Resistance mechanisms to autophagy-modulating therapies
$641,245Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2023 · CA
PI3K Pathway Mutations in Head and Neck Cancer
$641,113Jennifer R Grandis · University Of California, San Francisco · R01 · FY2023 · DE
PI3K Pathway Mutations in Head and Neck Cancer
$641,113Jennifer R Grandis · University Of California, San Francisco · R01 · FY2021 · DE
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer
$640,719Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · DE
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism
$640,703Nicholas C Denko · Ohio State University · R01 · FY2025 · CA
Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
$640,613Beth A. Reboussin · Wake Forest University Health Sciences · U01 · FY2025 · CA
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
$640,551Rebecca L Aft · Washington University · R01 · FY2022 · CA
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
$640,551Rebecca L Aft · Washington University · R01 · FY2023 · CA
Mining the microbiome for immunomodulatory microproteins
$640,522Ami Siddharth Bhatt · Stanford University · R01 · FY2025 · CA
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$640,450Ming You · Medical College Of Wisconsin · R01 · FY2020 · CA